NCT02693652View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

October 28, 2014

Primary Completion Date

August 22, 2017

Study Completion Date

August 22, 2017

Conditions
Hepatitis B, Chronic
Interventions
BIOLOGICAL

CVI-HBV-002

"* Investigational product: CVI-HBV-002~* Dose: 20ug or 40ug~* Frequency: 3 or 6 times~* Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months~* Administration route: Intramuscular injection"

Trial Locations (1)

13496

Bundang CHA General Hospital, Seongnam-si

All Listed Sponsors
lead

CHA Vaccine Institute Co., Ltd.

INDUSTRY

NCT02693652 - A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine | Biotech Hunter | Biotech Hunter